Mode
Text Size
Log in / Sign up
Phase 2 N=154 Randomized Quadruple-blind Prevention

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7

Enrolled (actual)
154
Serious AEs
0.7%
Results posted
Nov 2021
Primary outcome: Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Laboratory Biomarker Analysis (Other); Placebo Administration (Other); Rilimogene Galvacirepvec (Biological)
Age
Pediatric, Adult, Older Adult
Sex
Male
Sponsor
National Cancer Institute (NCI)
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies
12.2; -6.9
PRIMARY
Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies
4.6; 5.8
SECONDARY
Change in PD-L1 Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies
SECONDARY
Change in Prostate-specific Antigen (PSA)
0.26; -0.66
SECONDARY
Change in CD8+ Positive Cells in the Benign Portion of the Prostate Biopsies
7.22; 45.25
SECONDARY
Change in CD4+ Positive Cells in the Benign Portion of the Prostate Biopsies
73.41; -19.75
SECONDARY
Change in PD-L1 Positive Cells in the Benign Portion of the Prostate Biopsies
SECONDARY
Tumor Grade Progression
8; 6
SECONDARY
Change in Tumor Extent
-1.7; 1.6
SECONDARY
Proportion of Men With no Cancer in the Post-intervention Biopsy
25; 8
SECONDARY
Size of Dominant MRI Lesion
SECONDARY
Change in Circulating 15-Mer PSA-specific T Cells
SECONDARY
Change in Soluble Antibodies to Tumor-associated Antigens
SECONDARY
Immunologic Effects on the Target Organ Using Multiplex Immunofluorescence
SECONDARY
Change in International Prostate Symptom Score
-0.12; 0.87

Summary

This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells that express PSA.

Eligibility Criteria

Inclusion Criteria

  • Biopsy-proven (consisting of >= 10 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core, either random or targeted, in the most recent biopsy
  • All prior biopsies must meet the following: = = 1,200/mm^3 (>= 1.2 k/uL)
  • Stable platelet count >= 75, 000/mm^3 (>= 75 k/uL)
  • Bilirubin = = 70%
  • Must agree to use medically acceptable barrier and/or chemical method of contraception while on study and for at least one month following the last vaccine injection; should a participant's partner become pregnant or suspect she is pregnant while the participant is participating in this study, the study physician should be informed immediately; in the event a participant's partner becomes pregnant, the study sponsor may request additional information regarding the course of the pregnancy and if the pregnancy is carried to term, the birth of the child (i.e., the outcome of the pregnancy)
  • Ability to understand and the willingness to sign a written informed consent document
  • No planned prostate biopsies during the intervention until after the post-intervention biopsy
  • Men on stable doses of 5-alpha reductase inhibitors are eligible as long as there is no planned dose change while on study

Exclusion Criteria

  • Have had prior treatment for prostate cancer by surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy
  • Patients who have prostate cancer with distant metastases
  • Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years
  • Uncontrolled intermittent illnesses or medical conditions which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient; such illnesses/conditions may include, but are not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical history
  • Prior solid organ or bone marrow transplant
  • Immunodeficiency or splenectomy
  • Chronic immunosuppressive therapy within 30 days of screening
  • Inflammatory eye disease requiring steroid treatment within 28 days of screening
  • Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
  • History of or active autoimmune disease including but not limited to autoimmune neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome; persons with vitiligo are not excluded; Persons with well-controlled autoimmune endocrinopathies, e.g., diabetes mellitus, Graves' disease, Hashimoto's thyroiditis, Addison's disease are not excluded; persons with well-controlled rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica are not excluded
  • Known allergy to eggs, egg products
  • Prior or concurrent eczema or other eczemoid skin disorders or active skin condition (acute, chronic, or exfoliative) that disrupts the epidermis; persons with psoriasis are not excluded except in cases of:
  • any active lesion
  • any active lesion in the previous 6 months that required treatment, either systemic or topical
  • any prior episode, at any time, extensive enough or severe enough as to require systemic treatment
  • Previous adverse reactions to smallpox vaccination
  • Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination or until the vaccination site heals com
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02326805). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search